Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study program CSU is a chronic ...

Pediatric approval leveraged CupidKids pharmacokinetic bridging assessments, with adverse events consistent across ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

Targeted treatments have emerged as a safer and more effective option for eczema patients, but high costs remain a barrier.

We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...

The monoclonal antibody countered some esophageal restructuring caused by inflammatory dri ...

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ:APGE) ranks 6th on this list. Elite money managers are aggressively ...

First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent- global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD- U.S. net sales increased 52% ...